Should You Buy Avidity Biosciences Inc (RNA) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/26
Avidity Biosciences Inc (RNA) is not a good buy for a beginner investor with a long-term strategy at this time. The stock is trading near the acquisition price of $72 per share, as announced in the merger agreement with Novartis. There is limited upside potential, and analysts have downgraded the stock to Neutral. Additionally, insider selling and no recent positive catalysts further reduce the attractiveness of this investment.
Technical Analysis
The technical indicators are mixed. While moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD is below 0 and negatively contracting, and RSI is neutral at 59.625. The stock is trading close to its pivot level of 72.499, with resistance at 72.693 and support at 72.304. Overall, the technicals do not indicate a strong buy signal.
